Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability
- PMID: 25220215
- PMCID: PMC4289963
- DOI: 10.1038/npp.2014.240
Methylphenidate effects on brain activity as a function of SLC6A3 genotype and striatal dopamine transporter availability
Abstract
We pharmacologically challenged catecholamine reuptake, using methylphenidate, to investigate its effects on brain activity during a motor response inhibition task as a function of the 3'-UTR variable number of tandem repeats (VNTR) polymorphism of the dopamine transporter (DAT) gene (SLC6A3) and the availability of DATs in the striatum. We measured the cerebral hemodynamic response of 50 healthy males during a Go/No-Go task, a measure of cognitive control, under the influence of 40 mg methylphenidate and placebo using 3T functional magnetic resonance imaging. Subjects were grouped into 9-repeat (9R) carriers and 10/10 homozygotes on the basis of the SLC6A3 VNTR. During successful no-go trials compared with oddball trials, methylphenidate induced an increase of blood oxygen level-dependent (BOLD) signal for carriers of the SLC6A3 9R allele but a decrease in 10/10 homozygotes in a thalamocortical network. The same pattern was observed in caudate and inferior frontal gyrus when successful no-go trials were compared with successful go trials. We additionally investigated in a subset of 35 participants whether baseline striatal DAT availability, ascertained with (123)I-FP-CIT single photon emission computed tomography, predicted the amount of methylphenidate-induced change in hemodynamic response or behavior. Striatal DAT availability was nominally greater in 9R carriers compared with 10/10 homozygotes (d=0.40), in line with meta-analyses, but did not predict BOLD or behavioral changes following MPH administration. We conclude that the effects of acute MPH administration on brain activation are dependent on DAT genotype, with 9R carriers showing enhanced BOLD following administration of a prodopaminergic compound.
Figures


Similar articles
-
Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.J Nucl Med. 2009 Jan;50(1):45-52. doi: 10.2967/jnumed.108.053652. Epub 2008 Dec 17. J Nucl Med. 2009. PMID: 19091889
-
Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.Synapse. 2011 Oct;65(10):998-1005. doi: 10.1002/syn.20927. Epub 2011 Mar 28. Synapse. 2011. PMID: 21404331 Review.
-
VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT.Nucl Med Commun. 2022 Mar 1;43(3):247-255. doi: 10.1097/MNM.0000000000001514. Nucl Med Commun. 2022. PMID: 34908018
-
Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.J Nucl Med. 2005 May;46(5):745-51. J Nucl Med. 2005. PMID: 15872345 Clinical Trial.
-
Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.Am J Pharmacogenomics. 2004;4(2):83-92. doi: 10.2165/00129785-200404020-00003. Am J Pharmacogenomics. 2004. PMID: 15059031 Review.
Cited by
-
Combined neurodevelopmental exposure to deltamethrin and corticosterone is associated with Nr3c1 hypermethylation in the midbrain of male mice.Neurotoxicol Teratol. 2020 Jul-Aug;80:106887. doi: 10.1016/j.ntt.2020.106887. Epub 2020 Apr 26. Neurotoxicol Teratol. 2020. PMID: 32348866 Free PMC article.
-
miR-137 and miR-491 Negatively Regulate Dopamine Transporter Expression and Function in Neural Cells.Neurosci Bull. 2016 Dec;32(6):512-522. doi: 10.1007/s12264-016-0061-6. Epub 2016 Sep 15. Neurosci Bull. 2016. PMID: 27628529 Free PMC article.
-
Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease.Neurobiol Aging. 2018 Jun;66:12-22. doi: 10.1016/j.neurobiolaging.2018.02.003. Epub 2018 Feb 10. Neurobiol Aging. 2018. PMID: 29501966 Free PMC article.
-
A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2021 Apr;31(3):164-178. doi: 10.1089/cap.2020.0104. Epub 2020 Dec 31. J Child Adolesc Psychopharmacol. 2021. PMID: 33395356 Free PMC article. Clinical Trial.
-
Imaging genetics in neurodevelopmental psychopathology.Am J Med Genet B Neuropsychiatr Genet. 2017 Jul;174(5):485-537. doi: 10.1002/ajmg.b.32542. Am J Med Genet B Neuropsychiatr Genet. 2017. PMID: 29984470 Free PMC article. Review.
References
-
- Bari A, Robbins TW. Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol. 2013;108:44–79. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources